vs
Side-by-side financial comparison of Acadian Asset Management Inc. (AAMI) and ADMA BIOLOGICS, INC. (ADMA). Click either name above to swap in a different company.
Acadian Asset Management Inc. is the larger business by last-quarter revenue ($172.2M vs $139.2M, roughly 1.2× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 20.2%, a 15.3% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 2.6%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 27.6%).
United Asset Management was an American holding company headquartered in Boston, Massachusetts.
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
AAMI vs ADMA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $172.2M | $139.2M |
| Net Profit | $34.7M | $49.4M |
| Gross Margin | — | 63.8% |
| Operating Margin | 33.3% | 45.1% |
| Net Margin | 20.2% | 35.5% |
| Revenue YoY | 2.6% | 18.4% |
| Net Profit YoY | -18.4% | -55.9% |
| EPS (diluted) | $0.97 | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $172.2M | $139.2M | ||
| Q3 25 | $144.2M | $134.2M | ||
| Q2 25 | $127.4M | $122.0M | ||
| Q1 25 | $119.9M | $114.8M | ||
| Q4 24 | $167.8M | $117.5M | ||
| Q3 24 | $123.1M | $119.8M | ||
| Q2 24 | $109.0M | $107.2M | ||
| Q1 24 | $105.7M | $81.9M |
| Q4 25 | $34.7M | $49.4M | ||
| Q3 25 | $15.1M | $36.4M | ||
| Q2 25 | $10.1M | $34.2M | ||
| Q1 25 | $20.1M | $26.9M | ||
| Q4 24 | $42.5M | $111.9M | ||
| Q3 24 | $16.9M | $35.9M | ||
| Q2 24 | $11.0M | $32.1M | ||
| Q1 24 | $14.6M | $17.8M |
| Q4 25 | — | 63.8% | ||
| Q3 25 | — | 56.3% | ||
| Q2 25 | — | 55.1% | ||
| Q1 25 | — | 53.2% | ||
| Q4 24 | — | 53.9% | ||
| Q3 24 | — | 49.8% | ||
| Q2 24 | — | 53.6% | ||
| Q1 24 | — | 47.8% |
| Q4 25 | 33.3% | 45.1% | ||
| Q3 25 | 18.4% | 38.0% | ||
| Q2 25 | 12.7% | 35.1% | ||
| Q1 25 | 26.6% | 30.4% | ||
| Q4 24 | 38.7% | 32.6% | ||
| Q3 24 | 21.9% | 33.1% | ||
| Q2 24 | 18.9% | 36.6% | ||
| Q1 24 | 21.7% | 26.7% |
| Q4 25 | 20.2% | 35.5% | ||
| Q3 25 | 10.5% | 27.1% | ||
| Q2 25 | 7.9% | 28.1% | ||
| Q1 25 | 16.8% | 23.4% | ||
| Q4 24 | 25.3% | 95.2% | ||
| Q3 24 | 13.7% | 30.0% | ||
| Q2 24 | 10.1% | 29.9% | ||
| Q1 24 | 13.8% | 21.7% |
| Q4 25 | $0.97 | $0.20 | ||
| Q3 25 | $0.42 | $0.15 | ||
| Q2 25 | $0.28 | $0.14 | ||
| Q1 25 | $0.54 | $0.11 | ||
| Q4 24 | $1.11 | $0.45 | ||
| Q3 24 | $0.45 | $0.15 | ||
| Q2 24 | $0.29 | $0.13 | ||
| Q1 24 | $0.37 | $0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $87.6M |
| Total DebtLower is stronger | $200.0M | $72.1M |
| Stockholders' EquityBook value | — | $477.3M |
| Total Assets | $677.0M | $624.2M |
| Debt / EquityLower = less leverage | — | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $87.6M | ||
| Q3 25 | — | $61.4M | ||
| Q2 25 | — | $90.3M | ||
| Q1 25 | — | $71.6M | ||
| Q4 24 | — | $103.1M | ||
| Q3 24 | — | $86.7M | ||
| Q2 24 | — | $88.2M | ||
| Q1 24 | — | $45.3M |
| Q4 25 | $200.0M | $72.1M | ||
| Q3 25 | — | $72.4M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $275.0M | $72.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $477.3M | ||
| Q3 25 | — | $431.2M | ||
| Q2 25 | — | $398.3M | ||
| Q1 25 | — | $373.4M | ||
| Q4 24 | — | $349.0M | ||
| Q3 24 | — | $231.9M | ||
| Q2 24 | — | $188.3M | ||
| Q1 24 | — | $153.7M |
| Q4 25 | $677.0M | $624.2M | ||
| Q3 25 | $751.4M | $568.7M | ||
| Q2 25 | $672.3M | $558.4M | ||
| Q1 25 | $677.3M | $510.6M | ||
| Q4 24 | $703.2M | $488.7M | ||
| Q3 24 | $555.2M | $390.6M | ||
| Q2 24 | $533.1M | $376.4M | ||
| Q1 24 | $544.9M | $350.9M |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.4M | $35.6M |
| Free Cash FlowOCF − Capex | — | $34.6M |
| FCF MarginFCF / Revenue | — | 24.8% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | -0.07× | 0.72× |
| TTM Free Cash FlowTrailing 4 quarters | — | $27.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.4M | $35.6M | ||
| Q3 25 | $-23.9M | $13.3M | ||
| Q2 25 | $61.6M | $21.1M | ||
| Q1 25 | $-48.8M | $-19.7M | ||
| Q4 24 | $55.8M | $50.2M | ||
| Q3 24 | $69.6M | $25.0M | ||
| Q2 24 | $45.7M | $45.6M | ||
| Q1 24 | $-40.4M | $-2.2M |
| Q4 25 | — | $34.6M | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | — | $18.7M | ||
| Q1 25 | — | $-24.4M | ||
| Q4 24 | — | $47.5M | ||
| Q3 24 | — | $24.0M | ||
| Q2 24 | — | $43.6M | ||
| Q1 24 | — | $-4.6M |
| Q4 25 | — | 24.8% | ||
| Q3 25 | — | -0.8% | ||
| Q2 25 | — | 15.3% | ||
| Q1 25 | — | -21.2% | ||
| Q4 24 | — | 40.4% | ||
| Q3 24 | — | 20.0% | ||
| Q2 24 | — | 40.7% | ||
| Q1 24 | — | -5.6% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 10.7% | ||
| Q2 25 | — | 2.0% | ||
| Q1 25 | — | 4.1% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 1.9% | ||
| Q1 24 | — | 2.9% |
| Q4 25 | -0.07× | 0.72× | ||
| Q3 25 | -1.58× | 0.36× | ||
| Q2 25 | 6.10× | 0.62× | ||
| Q1 25 | -2.43× | -0.73× | ||
| Q4 24 | 1.31× | 0.45× | ||
| Q3 24 | 4.12× | 0.70× | ||
| Q2 24 | 4.15× | 1.42× | ||
| Q1 24 | -2.77× | -0.12× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AAMI
Segment breakdown not available.
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
